Document is current
Any future updates will be listed below
-
Authors
Montierth, Matthew D.
Yan, Hao
Xie, Liyang
Nemeth, Kinga
Pan, Xiaoxi
Li, Ruonan
Ercan, Caner
Yang, Peng
Sinjab, Ansam
Zhou, Tieling
Peng, Fuduan
Singh, Manisha
Wang, Linghua
Kopetz, Scott
Kadara, Humam
Yuan, Yinyin
Calin, George A.
Wang, Wenyi https://orcid.org/0000-0003-0617-9438
-
Funding
Funding for this research was provided by:
National Cancer Institute (1R01CA268380)
National Cancer Institute (1R01CA222007-01A1)
U.S. Department of Defense (BC200208P1)
Lyda Hill Philanthropies (FP00020550)
Center for Cancer Research (1R01CA183793)
- License Information
-
More Information
Article History
Received: 21 November 2025
Accepted: 30 July 2026
First Online: 10 August 2026
Declarations
Ethics approval and consent to participate: The study is conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of University of Texas, MD Anderson Cancer Center (IRB protocol PA14-0404 under PI Dr. Wenyi Wang). No patient was recruited for this study.
Consent for publication: This study used published data from patient samples and only generated new data from cell-line mixtures. Patient consent is not applicable.
Competing interests: Dr. Calin is the scientific founder of Ithax Pharmaceuticals, Inc. All other authors declare no competing interests.
